{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:50:28Z","timestamp":1791355828560,"version":"4.3.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lymphatic malformations are rare vascular anomalies. Currently, there is no uniform approach to the treatment of these patients. Neonates with extensive disease often suffer from multiple complications, organ dysfunction, and various tissue lesions, which may be life-threatening and lead to aesthetic deformity. Treatment with sirolimus has the potential to improve symptoms and downsize the lesion, up to complete regression. This retrospective single-center study presents our experience with oral sirolimus in the treatment of newborns with lymphatic malformations, evaluating its efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was conducted on 23 patients in the neonatal period and early infancy with lymphatic malformations, treated at the St. Petersburg State Pediatric Medical University between 2021 and 2025. Seven patients underwent primary radical surgical treatment and were not included in the analysis. The final study cohort consisted of 16 patients who received primary conservative therapy with sirolimus. Fifteen out of 16 patients started receiving oral sirolimus before the age of 28 days of life. The median age at the commencement of treatment was 15 days after birth. After instrumental and laboratory examination, sirolimus was administered at a starting reduced dose of 0.5\u2005mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day divided into two daily doses, followed by a gradual increase under clinical and laboratory monitoring. The therapeutic concentration of sirolimus in the blood (5\u201315\u2005ng\/mL) was monitored once a week.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Disease stabilization or regression was achieved in all 16 patients (100%), with a partial or complete radiological response (\u226550% volume reduction) in 13 patients (81.25%) and complete regression (&amp;gt;90% volume reduction) in 10 patients (62.5%) at the 6-month assessment. No treatment-related serious adverse events requiring permanent discontinuation were observed. Recorded adverse events included transient respiratory infections (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), diarrhea (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), aphthous stomatitis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), and mild anemia (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), all of which resolved with supportive care or temporary dose adjustment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this selected cohort, sirolimus demonstrated an acceptable safety and efficacy profile, supporting its feasibility as a conservative first-line strategy in neonates with extensive or unresectable lymphatic malformations. However, larger prospective studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1900903","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:58:33Z","timestamp":1791352713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective evaluation of sirolimus (mTOR blocker) for lymphatic malformations presenting in the neonatal period: a single-center experience"],"prefix":"10.3389","volume":"14","author":[{"given":"Alexey","family":"Podkamenev","sequence":"first","affiliation":[{"name":"Department of Surgical Diseases of Childhood Named After G.A.Bairov, St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arina","family":"Syrtsova","sequence":"additional","affiliation":[{"name":"Department of Surgical Diseases of Childhood Named After G.A.Bairov, St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gleb","family":"Kondratiev","sequence":"additional","affiliation":[{"name":"Department of Oncology, Pediatric Oncology and Radiation Therapy, St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Nabokov","sequence":"additional","affiliation":[{"name":"Department of Surgical Diseases of Childhood Named After G.A.Bairov, St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Ti","sequence":"additional","affiliation":[{"name":"Perinatal Center of the St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Kuzminykh","sequence":"additional","affiliation":[{"name":"Perinatal Center of the St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav","family":"Dvoretsky","sequence":"additional","affiliation":[{"name":"Perinatal Center of the St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Ajamoghlian","sequence":"additional","affiliation":[{"name":"Perinatal Center of the St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kostylev","sequence":"additional","affiliation":[{"name":"Department of Oncohematology, St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Myznikova","sequence":"additional","affiliation":[{"name":"Perinatal Center of the St. Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.rxeng.2018.02.008","article-title":"Vascular malformations and tumors. Part 2: low-flow lesions","volume":"61","author":"Flors","year":"2019","journal-title":"Radiologia (Engl. Ed.)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0022-3468(99)90590-0","article-title":"25 Years\u2019 experience with lymphangiomas in children","volume":"34","author":"Alqahtani","year":"1999","journal-title":"J Pediatr Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/0194599812453552","article-title":"Head and neck lymphatic malformation treatment: a systematic review","volume":"147","author":"Adams","year":"2012","journal-title":"Otolaryngol Head Neck Surg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21682\/2311-1267-2020-7-3-22-31","article-title":"Sirolimus for the treatment of vascular anomalies in children","volume":"7","author":"Donyush","year":"2020","journal-title":"Russ. J. Pediatr. Hematol. Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00006534-198203000-00002","article-title":"Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics","volume":"69","author":"Milliken","year":"1982","journal-title":"Plast Reconstr Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jvsv.2021.01.013","article-title":"Management of lymphatic vascular malformations: a systematic review of the literature","volume":"9","author":"Kalwani","year":"2021","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/jdb10010011","article-title":"Genetic and molecular determinants of lymphatic malformations: potential targets for therapy","volume":"10","author":"Lee","year":"2022","journal-title":"J Dev Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/MOO.0b013e328010ba6b","article-title":"Head and neck hemangiomas of infancy","volume":"14","author":"MacArthur","year":"2006","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1007\/s00405-023-07991-1","article-title":"Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review","volume":"280","author":"Saibene","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/hmg\/ddu505","article-title":"Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations","volume":"24","author":"Osborn","year":"2015","journal-title":"Hum Mol Genet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"161589","DOI":"10.1016\/j.jpedsurg.2024.05.019","article-title":"American pediatric surgical association outcomes and evidence-based practice committee. Management and outcomes of pediatric lymphatic malformations: a systematic review from the APSA outcomes and evidence-based practice committee","volume":"59","author":"Huerta","year":"2024","journal-title":"J Pediatr Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/CIRCRESAHA.121.318142","article-title":"Lymphatic malformations: genetics, mechanisms and therapeutic strategies","volume":"129","author":"M\u00e4kinen","year":"2021","journal-title":"Circ Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"a009688","DOI":"10.1101\/cshperspect.a009688","article-title":"Vascular anomalies: from genetics toward models for therapeutic trials","volume":"2","author":"Uebelhoer","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncponc1112","article-title":"Rapamycin treatment for a child with germline PTEN mutation","volume":"5","author":"Marsh","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"V\u00e9zina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1134\/S0006297914020023","article-title":"Kinase mtor: regulation and role in maintenance of cellular homeostasis, tumor development, and aging","volume":"79","author":"Parkhitko","year":"2014","journal-title":"Biochemistry (Moscow)"},{"key":"B19","first-page":"589","article-title":"TOR-centric concept of regulation of mitogenic, metabolic and energy signaling pathways in the cell","volume":"54","author":"Zubova","year":"2012","journal-title":"Cytology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jvs.2019.06.217","article-title":"Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review","volume":"71","author":"Freixo","year":"2020","journal-title":"J Vasc Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1034\/j.1399-0012.2000.140201.x","article-title":"Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity","volume":"14","author":"Kahan","year":"2000","journal-title":"Clin Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1089\/lrb.2018.0068","article-title":"Oral sirolimus: an option in the management of neonates with life-threatening upper airway lymphatic malformations","volume":"17","author":"Triana","year":"2019","journal-title":"Lymphat Res Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijporl.2017.12.011","article-title":"Sirolimus for management of complex vascular anomalies\u2014a proposed dosing regimen for very young infants","volume":"105","author":"Patel","year":"2018","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.5863\/1551-6776-27.5.455","article-title":"Evaluation of sirolimus dosing in neonates and infants with lymphatic disorders: a case series","volume":"27","author":"Serio","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ped4.12397","article-title":"Rapid response with good toleration of sirolimus for life-threatening neonatal lymphatic malformations: a case series","volume":"7","author":"Dong","year":"2023","journal-title":"Pediatr Investig"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1097\/JOVA.0000000000000140","article-title":"Early sirolimus therapy combined with sclerotherapy for the management of extensive neonatal cervicofacial lymphatic malformations: clinical and MR-volumetric follow-up in a series of 10 patients","volume":"7","author":"Fraissenon","year":"2026","journal-title":"J. Vasc. Anom"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.17816\/PED1355-21","article-title":"Newborns death risk factors after surgical interventions in the early neonatal period","volume":"13","author":"Bezhenar","year":"2022","journal-title":"Pediatrician (St. Petersburg)"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1900903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:58:34Z","timestamp":1791352714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1900903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":28,"alternative-id":["10.3389\/fped.2026.1900903"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1900903","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1900903"}}